Intended for healthcare professionals

Minerva

Problematic PSA . . . and other stories

BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m570 (Published 20 February 2020) Cite this as: BMJ 2020;368:m570

Prostate specific antigen testing

The problem with prostate specific antigen screening (PSA) is selecting a cut-off that provides adequate sensitivity without leading to the over diagnosis of cancers that are unlikely to cause harm. A re-analysis of data from a large trial in the US finds that men aged 55 to 60 whose PSA was less than 2 ng/ml at initial testing were very unlikely to develop clinically significant prostate cancer over 13 years of follow-up (JAMA Netw Open doi:10.1001/jamanetworkopen.2019.19284). The investigators hope this could improve PSA testing in younger men if those with low baseline PSA levels were classified …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription